Hemangioblastomas in the pituitary stalk are extremely rare; only 13 cases have been described in the past. [1] [2] [3] [4] [5] [6] Detected by a dynamic contrast-enhanced magnetic resonance imaging (MRI), a case of pituitary infundibulum hemangioblastomas (HBL) was reported by us with tumor volume only 0.016 cm 3 .
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BRIEF COMMUNICATIONS
4, luteinizing hormone, follicle-stimulating hormone, estradiol, progesterone, human growth hormone, cortisol, and testosterone were within normal ranges; the concentration of prolactin in the serum (29.44ng/ml, normal range 1.39-24.20ng/ml) was still slightly elevated. She was prescribed 2.5 mg/day of bromocriptine. Two weeks later the symptom of galactorrhea was relieved to some degree, and the concentration of prolactin in the serum dropped to 19.23ng/ml (normal range 1.39-24.20ng/ml).
DISCUSSION
Compared with pituitary stalk HBLs reported so far 1-6 the tumor volume in our case was the smallest. On MRI the tumor could be found just to the left of the pituitary infundibulum. We could easily clarify its origin, where the tumor arose from in the pituitary stalk, because of its tiny volume.
In the Lonser's series 6 these tumor volume ranged from 0.08 to 2.8 cm 3 , however, no patients presented with or developed signs or symptoms attributable to a pituitary stalk tumor and laboratory endocrine profiles of all patients were normal. In our case HBL volume was only 0.016 mm 3 and the patient complained of the galactorrhea and alopecia that was thought as a presentation of hyperprolactinemia and hypopituitarism. Some women have excess prolactin secretion but with normal pituitary MRI. 7 Our patient was in a different situation: her symptoms of galactorrhea, increase of prolactin secretion, and pituitary stalk lesion showen by the pituitary MRI corroborated each other. Therefore we speculated that the small tumor might be the etiology of the hyperprolactinemia. From a functional point of view, the tumor, even when it was very small, had influenced stalk input of hypothalamic dopamine.
In our case the tumor was too small to catch by a conventional enhancement MRI. It was the dynamic contrast enhancement MRI which helped capture the image of the tumor. Dynamic contrast enhancement MRI is performed after the administration of intravenous contrast medium to noninvasively access tumor vascular characteristics. 8 It can provide useful hemodynamic information about intra-axial brain tumors that is not provided by standard MRI and therefore contributes to the differential diagnosis. 9 The normal pituitary stalk lacks a blood-brain barrier, and it enhances intensely with administration of gadolinium. 10 However, being a vascular tumor, hemangioblastoma has an immediately and more quickly increasing enhancement after injection of gadolinium; the hemangioblastoma's enhancement happens earlier than the pituitary stalk's when using dynamic THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES contrast MRI. Therefore, dynamic contrast enhancement MRI has the capability to distinguish a tiny hemangioblastoma from the pituitary stalk.
Excluding the case presented in Neumann's report 3 in which details were not described, previous cases of pituitary stalk hemangioblastomas took surgical resection or observation without surgery. [1] [2] [3] [4] [5] [6] In our case we chose medical treatment. Oral bromocriptine brought relief of symptoms to the patient.
Pituitary infundibulum hemangioblastoma can affect the function of the pituitary gland, even when tumor volume is very small. For hemangioblastomas, particularly in VHL disease, dynamic contrast enhancement MRI with thin coronal scans through the sella is necessary when patients present pituitary dysfunction symptoms. Oral bromocriptine can control the symptoms of hyperprolactinemia caused by pituitary infundibulum hemangioblastoma.
